期刊文献+

腺相关病毒携带hTERT启动子调控的TRAIL基因特异性杀伤肿瘤细胞 被引量:4

Specific Antitumor Effect of Adeno-Associated Virus Vector Carrying TRAIL Gene under the Control of hTERT Promoter
下载PDF
导出
摘要 背景与目的:腺相关病毒(adeno-associated virus)作为载体已被广泛用于肿瘤的基因治疗研究。肿瘤坏死因子相关凋亡诱导配体(tumor necrosis factorrelated apoptosis-inducing ligand,TRAIL)基因可迅速诱导多种肿瘤细胞的凋亡,是一个安全有效的肿瘤杀伤基因。本研究旨在构建能在肿瘤细胞内特异性表达TRAIL基因的靶向腺相关病毒,并探讨其体外抗肿瘤效应的可能机制。方法:利用肿瘤特异性启动子端粒酶逆转录酶(human telomerase reverse transcriptase,hTERT)构建特异性杀伤肿瘤细胞的腺相关病毒载体pAAV-hTERT-TRAIL。通过与pAAV-RC、pHelper共转染HEK293细胞包装出病毒AAV-hTERT-TRAIL。将该病毒体外转染人结肠癌SW620细胞、人肝癌HepG2细胞、人肺癌A549细胞和正常细胞NHLF、MRC5后,检测TRAIL基因的肿瘤特异性表达。MTT法检测其对细胞增殖的影响,ELISA、Westernblot法以及流式细胞仪检测细胞的凋亡,并分析其体外抗肿瘤效应的可能机制。结果:成功包装出病毒AAV-hTERT-TRAIL。RT-PCR、Western blot和免疫组化法均证实AAV-hTERT-TRAIL能介导TRAIL基因在肿瘤细胞内特异性表达,但在正常细胞内不表达。以100 MOI AAV-hTERT-TRAIL感染细胞96h后,SW620、A549和HepG2细胞的增殖率分别是41.55%、44.29%、49.95%,NHLF和MRC5细胞的增殖率分别是84.59%和87.22%。Westernblot检测发现AAV-hTERT-TRAIL可激活Caspase通路,流式细胞仪和ELISA方法检测证实AAV-hTERT-TRAIL可诱导细胞凋亡。结论:hTERT的存在增强了腺相关病毒所携带TRAIL基因表达的肿瘤靶向性和对正常细胞的安全性,由它调控的杀伤基因可介导肿瘤细胞特异性的细胞毒效应。 BACKGROUND & OBJECTIVE: Adeno-associated virus (AAV) has been widely used in tumor gene therapy. Tumor necrosis factorrelated apoptosis-inducing ligand (TRAIL) is a safe and potent anti-tumor gene which could induce apoptosis of many tumor cells. This study was to use tumor-specific promoter hTERT to construct AAV-hTERT-TRAIL, and explore its antitumor effect and mechanism in vitro. METHODS. Purified AAV- hTERT-TRAIL was obtained after co-transfection of HEK293 with pAAV-hTERTTRAIL and two other help plasmids. After transfection of AAV-hTERT-TRAIL into three tumor cell lines, SW620, HepG2, A549 and two normal cell lines, NHLF and MRC5, the expression of TRAIL was detected by RT-PCR, Western blot and immunohistochemistry (IHC); the influence of AAV-hTERT- TRAIL transfection on cell proliferation was evaluated using M-I-I- assay. Activation of caspase-3 and PARP was measured by Western blot. Cell apoptosis was assessed using ELISA and flow cytometry. RESULTS: AAV- hTERT-TRAIL was successfully packaged in HEK293 cells. After AAV-hTERT- TRAIL infection, specific expression of TRAIL was detected in three tumor cell lines, but not in two normal cell lines. Cell proliferation rates in SW620, A549, HepG2, NHLF and MRC5 cells were 41.55%,44.29%,49.95%,84.59% and 87.22%, respectively after transfection of AAV-hTERT-TRAIL at a multiplicity of infection (MOI) of 100 for 96 h. AAV-hTERT-TRAIL activated caspase-3 apoptotic pathway and induced apoptosis in tumor cell lines, but not in normal cell lines. CONCLUSIONS: hTERT increases selectivity and safety of AAV vector, hTERT promoter controls the expression of anti-tumor genes to specifically induce death of tumor cells.
出处 《癌症》 SCIE CAS CSCD 北大核心 2008年第10期1026-1033,共8页 Chinese Journal of Cancer
基金 国家"863"项目(No.2007AA021006) 中国科学院重要方向性项目(No.KSCX2-YW-R-09)~~
关键词 肿瘤 SW620细胞 A549细胞 HepG2细胞 腺相关病毒 TRAIL HTERT启动子 凋亡 Neoplasm SW620 cells A549 cells HepG2 cells Adenoassociated virus TRAIL hTERT promoter Apoptosis
  • 相关文献

参考文献4

二级参考文献26

  • 1Clark K R,Human Gener,1999年,10卷,1031页 被引量:1
  • 2Synder R O,Current Protocols in Human Genetics,1996年 被引量:1
  • 3Nguyen JT. Adeno-associated virus and other potential vectors for angiostatin and endostatin gene therapy [J]. Adv Exp Med Biol, 2000, 465:457-466. 被引量:1
  • 4Nguyen JT, Wu P, Clouse ME, et al. Adono-associated delivery of antiangiogenic factors as an antitumor strategy [J]. Cancer Res, 1998, 58:5673-5677. 被引量:1
  • 5Folkman J. Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis [J]. N Engl J Med,1995,333:1757-1763. 被引量:1
  • 6Baillie CT, Winslet MC, Bradley NJ. Tumor vasculature-a potential therapeutic target [J]. Br J Cancer,1995, 72:257-267. 被引量:1
  • 7Malik AK, Monahan PE, Allen DL, et al. Kinetics of recombinant adeno-associated virus mediated gene transfer [J]. J Virol,2000, 74: 3555-3565. 被引量:1
  • 8Brockstedt DG, Podsakoff GM, Fong L, et al. Induction of immunity to antigens expressed by recombinant adeno-associated virus depends on the route of administration [J]. Clin Immunol, 1999,92:67-75. 被引量:1
  • 9O'Reilly MS,Boehm T,Shing Y,et al.Endostatin:an endogenous inhibitor of angiogenesis and tumor growth [J]. Cell, 1997, 88: 277-285. 被引量:1
  • 10Boehm T, Folkman J, Browder T, et al. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance [J]. Nature, 1997, 390:404-407. 被引量:1

共引文献84

同被引文献30

  • 1王艳萍,唐小军,陈晓禾,车国卫,朱大兴,孙芝琳,周清华.hTERT启动子的克隆及其在端粒酶阳性肺癌细胞中的靶向转录活性研究[J].四川大学学报(医学版),2006,37(4):497-501. 被引量:7
  • 2Xin Yuan Liu~(1,2) ~1Institute of Biochemistry and Cell Biology,Shanghai Institutes for Biological Sciences,Chinese Academy of Sciences,320 Yue Yang Road,Shanghai 200031,China,~2Xinyuan Institute of Medicine and Biotechnology,School of Life Science,Zhejiang Sci-Tech University,Hangzhou 310018,China.Targeting Gene-Virotherapy of Cancer and its prosperity[J].Cell Research,2006,16(11):879-886. 被引量:32
  • 3朱圣明,王艳萍,陈晓禾,唐小军,肖文.人端粒酶催化亚单位启动子驱动的EGFP真核表达载体的构建及在肺癌细胞的表达[J].医学研究生学报,2007,20(2):123-127. 被引量:11
  • 4Wiley SR, Schooley K, Smolak PJ, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity, 1995,3 (6) : 673-682. 被引量:1
  • 5Yoldas B, Ozer C, Ozen O, et al. Clinical significance of TRAIL and TRAIL receptors in patients with head and neck cancer. Head Neck, 2011,33(9) : 1278-1284. 被引量:1
  • 6Shivapurkar N, Toyooka S, Toyooka KO, et al. Aberrant methylation of trail decoy receptor genes is frequent in multiple tumor types. Int J Cancer, 2004,109 (5) : 786-792. 被引量:1
  • 7Trarbach T, Moehler M, Heinemann V, et al. Phase 11 trial of mapatumumab, a fully human agonistie monoelonal antibodythat targets and activates the tumour necrosis factor apoptosis- inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer. Br J Cancer, 2010,102(3) :506-512. 被引量:1
  • 8Jiang M, Liu Z, Xiang Y, et al. Synergistic antitumor effect of AAV-mediated TRAIL expression combined with cisplatin on head and neck squamous cell carcinoma. BMC Cancer, 2011,11:54. 被引量:1
  • 9Lashinger LM, Zhu K, Williams SA, et al. Bortezomib abolishes tumor necrosis factor-related apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells. Cancer Res, 2005,65 ( 11 ) : 4902-4908. 被引量:1
  • 10Nikrad M, Johnson T, Puthalalath H, et al. The proteasome inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only proteins Bik and Bim. Mol Cancer Ther, 2005,4(3) :443-449. 被引量:1

引证文献4

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部